Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (321-330 of 688) with videos related to

Pageof 69
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 29, 2018
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trialsXavier Rossello, Cono Ariti, Stuart J Pocock, et al.
American Journal of Nephrology|October 28, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease TrialGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
American Journal of Hypertension|November 1, 2024
Bladder Symptoms Provoked by Short, Rapid-Acting Loop Diuretics: A Frequent but Often Overlooked ProblemChristopher S Wilcox, Negiin Pourafshar, Karina Han, et al.
European Journal of Heart Failure|January 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysisRobert J Mentz, Stefan D Anker, Bertram Pitt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 26, 2024
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED TrialVikas S Sridhar, Deepak L Bhatt, Ayodele Odutayo, et al.
Circulation|July 2, 2015
Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of SpironolactoneAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
Journal of the American College of Cardiology|August 2, 2005
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failureBertram Pitt, Harvey White, Jose Nicolau, et al.
European Journal of Heart Failure|March 1, 2006
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%Bertram Pitt, Mihai Gheorghiade, Faiez Zannad, et al.
ESC Heart Failure|September 18, 2025
Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary studyChristina G Hutten, Annika Tekumulla, Anis Ismail, et al.
JACC. Heart Failure|October 17, 2017
Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT StudyAli Vazir, Brian Claggett, Bertram Pitt, et al.
Pageof 69

Showing results (321-330 of 688) with videos related to

Sort By:
Pageof 69
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 29, 2018
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trialsXavier Rossello, Cono Ariti, Stuart J Pocock, et al.
American Journal of Nephrology|October 28, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease TrialGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
American Journal of Hypertension|November 1, 2024
Bladder Symptoms Provoked by Short, Rapid-Acting Loop Diuretics: A Frequent but Often Overlooked ProblemChristopher S Wilcox, Negiin Pourafshar, Karina Han, et al.
European Journal of Heart Failure|January 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysisRobert J Mentz, Stefan D Anker, Bertram Pitt, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 26, 2024
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED TrialVikas S Sridhar, Deepak L Bhatt, Ayodele Odutayo, et al.
Circulation|July 2, 2015
Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of SpironolactoneAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
Journal of the American College of Cardiology|August 2, 2005
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failureBertram Pitt, Harvey White, Jose Nicolau, et al.
European Journal of Heart Failure|March 1, 2006
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%Bertram Pitt, Mihai Gheorghiade, Faiez Zannad, et al.
ESC Heart Failure|September 18, 2025
Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary studyChristina G Hutten, Annika Tekumulla, Anis Ismail, et al.
JACC. Heart Failure|October 17, 2017
Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT StudyAli Vazir, Brian Claggett, Bertram Pitt, et al.
Pageof 69